28.11.2011: Epimakuläre Brachytherapie:
"Einsatz außerhalb klinischer Studien nicht zu verantworten"
Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur
epimakulären Brachytherapie bei altersbedingter Makuladegeneration
Eylea ™ (VEGF Trap-Eye)
Overview Eylea for the Treatment of Wet Age-Related Macular Degeneration
25.11.2011
FDA одобрило препарат Eylea для лечения возрастной макулярной дегенерации
Агентство по контролю за продуктами питания и лекарственными средствами США (FDA) одобрило препарат Eylea (афлиберцепт) для лечения влажной формы возрастной макулярной дегенерации
читать далее: FDA одобрило препарат Eylea для лечения возрастной макулярной дегенерации
Ärzte Zeitung, 21.11.2011
USA: Neues Mittel gegen Makuladegeneration
BERLIN (eb). Regeneron Pharmaceuticals, Kooperationspartner von Bayer, hat von der US-Gesundheitsbehörde FDA die Zulassung für Eylea™ zur Therapie bei feuchter (neovaskulärer) altersbedingter Makuladegeneration erhalten. Das teilt die Bayer Pharma AG mit.
Weiterlesen: USA: Neues Mittel gegen Makuladegeneration
Nov. 19, 2011
Regeneron Wins FDA Approval for Blindness Drug Eylea
Regeneron Pharmaceuticals Inc. (REGN) won U.S. approval of Eylea, a treatment for a common cause of blindness that will rival Roche Holding AG (ROG)'s Lucentis.
Read more: Regeneron Wins FDA Approval for Blindness Drug Eylea
18. November 2011
EYLEA in den USA zur Behandlung der feuchten altersbedingten Makula-Degeneration zugelassen
Regeneron Pharmaceuticals hat von der US-Gesundheitsbehörde FDA (Food and Drug Administration) die Zulassung für EYLEA ™, auch bekannt als VEGF Trap-Eye, zur Behandlung der feuchten (neovaskulären) altersbedingten Makula-Degeneration (AMD) erhalten.
Weiterlesen: EYLEA in den USA zur Behandlung der feuchten altersbedingten Makula-Degeneration zugelassen
Nov. 18, 2011
U.S. FDA Approves EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for EYLEA™ Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).
Nov. 18, 2011
FDA approves Eylea for eye disorder in older people
The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.
Read more: FDA approves Eylea for eye disorder in older people
Nov. 16, 2011
Media Advisory: For Nov. 18 FDA Decision on Vision Drug, AHAF Experts Available for Comment
For the anticipated FDA announcement on November 18 regarding new treatment for macular degeneration, the American Health Assistance Foundation has experts available for comment, as well as inspiring stories of persons living with the disease.
Read more: Media Advisory: For Nov. 18 FDA Decision on Vision Drug, AHAF Experts Available for Comment
Oct. 24, 2011, AAO
VEGF Trap-Eye Clinical Trial Results Will Be Presented at the American Academy of Ophthalmology 2011 Annual Meeting
The comprehensive year-one findings of the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) 1 and 2 studies will be reported by Ursula Schmidt-Erfurth, MD, of the Medical University of Vienna, Austria. Results of the Controlled Phase 3 Evaluation of Repeated intravitreal administration of VEGF Trap-Eye in Central retinal vein occlusion: Utility and Safety (COPERNICUS) study will be reported by Julia Haller, MD, of the Wills Eye Institute in Philadelphia.
August 23, 2011 Macular Degeneration Support Canada
Eylea Treatment for Macular Degeneration
A new drug has been developed as a treatment for macular degeneration. The drug named Eylea will compete directly with Lucentis, the current leading treatment for the eye disease.
read more: Eylea Treatment for Macular Degeneration
August 17, 2011 Bloomberg
Regeneron Says FDA Delays Eylea Drug for Blindness
The drug, known as Eylea, would compete with Lucentis from Basel, Switzerland-based Roche Holding AG. (ROG) Eylea is injected every eight weeks, half as often as Lucentis
read more: Regeneron Says FDA Delays Eylea Drug for Blindness
August 16, 2011 Regeneron
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Regeneron Pharmaceuticals, Inc. today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascular age-related macular degeneration (wet AMD) to November 18, 2011
read more: Regeneron Announces Review of Biologics License Application for EYLEA
29.06.2011 finanznachrichten.de
EYLEA (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA'', also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).
June 17, 2011 eyedrd
Eylea: A New Drug for Wet Macular Degeneration
A Food and Drug Administration panel voted unanimously Friday to recommend to approve a new Regeneron Pharmaceuticals Inc. eye drug Eylea for the treatment of a condition that can lead to blindness
read more: Eylea - A New Drug for Wet Macular Degeneration
June 17, 2011 RTTNews
FDA Panel Backs Regeneron's Eye Drug Eylea For Wet-AMD
Regeneron Pharmaceuticals Inc. (REGN: News ), said Friday that a panel of the U.S. Food and Drug Administration has unanimously recommended for approval its eye medication Eylea, indicated in the treatment of Wet AMD - a severe eye disorder that results in loss of vision.
read more: FDA Panel Backs Regeneron's Eye Drug Eylea For Wet-AMD
Gefällt Ihnen diese Seite zum Thema "Altersbedingte Makuladegeneration"? Bitte empfehlen Sie diese Informationen zur AMD dann Ihren Freunden und Bekannten:
